GSOR12   Presentation Time: 12:55 PM

Uterine cancer remains the most commonly diagnosed gynecologic malignancy. Surgical resection is the mainstay of treatment and is followed by risk-adapted adjuvant therapy. Although randomized data exists comparing brachytherapy +/- EBRT, there is no high-level evidence guiding the use of VCB after EBRT. Retrospective data supports VCB following EBRT for locally advanced uterine cancers in the presence of cervical stromal invasion (+CSI) and/or positive margins (+SM). Lymphovascular space invasion (LVSI) predicts for lymph node involvement and cancer recurrence, but its status as an independent risk factor associated with response to VCB is unknown.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research